Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients

References

• Silberstein L E, Jefferies L C, Goldman J, Friedman D, Moore J S, Nowell P C. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood 1991; 78: 2372–2386
   PubMed Web of Science ®Google Scholar
• Packman C H, Leddy J P. Cryopathic hemolytic syndromes. Williams Hematology, 5th edn, E Beutler, M A Lichtman, B S Coller, T J Kipps. McGraw Hill, New York, NY 1995; 685–690
   Google Scholar
• Berentsen S, Tjonnfjord G E, Shammas F V, Bergheim J, Hammerstrom J, Langholm R. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol 2000; 65: 88–90
   PubMed Web of Science ®Google Scholar
• Evans R S, Baxter E, Gilliland B C. Chronic hemolytic anemia due to cold agglutinins: a 20-year history of benign gammopathy with response to chlorambucil. Blood 1973; 42: 463–470
   PubMed Web of Science ®Google Scholar
• Hippe E, Jensen K B, Olesen H, Lind K, Thomsen P E. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood 1970; 35: 68–72
   PubMed Web of Science ®Google Scholar
• Hillen H F, Bakker S J. Failure of interferon-alpha-2b therapy in chronic cold agglutinin disease. Eur J Haematol 1994; 53: 242–243
   PubMed Web of Science ®Google Scholar
• O'Connor B M, Clifford J S, Lawrence W D, Logue G L. Alpha-interferon for severe cold agglutinin disease. Ann Intern Med 1989; 111: 255–256
   PubMed Web of Science ®Google Scholar
• Dacie J. The Auto-Immune Haemolytic Anaemias, 3rd edn. Churchill Livingstone, Edinburgh 1992; 452–520
   Google Scholar
• Berentsen S, Bo K, Shammas F V, Myking A O, Ulvestad E. Chronic cold agglutinin disease of the ‘idiopathic’ type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS 1997; 105: 354–362
   PubMed Web of Science ®Google Scholar
• Coiffier B. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 2004; 31: 7–11
   PubMed Web of Science ®Google Scholar
• Rastetter W, Molina A, White C A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55: 477–503
   PubMed Web of Science ®Google Scholar
• Seymour J F. New treatment approaches to indolent non-Hodgkin's lymphoma. Semin Oncol 2004; 31: 27–32
   PubMed Web of Science ®Google Scholar
• Edwards J C, Leandro M J, Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 2002; 30: 824–828
   PubMed Web of Science ®Google Scholar
• Edwards J C, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D R. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572–2581
   PubMed Web of Science ®Google Scholar
• Gharib M, Poynton C. Complete, long-term remission of refractory idiopathic cold haemagglutinin disease after Mabthera. Br J Haematol 2002; 117: 248–249
   PubMed Web of Science ®Google Scholar
• Layios N, Van Den N E, Jost E, Deneys V, Scheiff J M, Ferrant A. Remission of severe cold agglutinin disease after Rituximab therapy. Leukemia 2001; 15: 187–188
   PubMed Web of Science ®Google Scholar
• Lee E J, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998; 92: 3490–3491
   PubMed Web of Science ®Google Scholar
• Mori A, Tamaru J, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol 2002; 68: 243–246
   PubMed Web of Science ®Google Scholar
• Pulik M, Genet P, Lionnet F, Touahri T. Treatment of primary chronic cold agglutinin disease with rituximab: maintenance therapy may improve the results. Br J Haematol 2002; 117: 998–999
   PubMed Web of Science ®Google Scholar
• Sparling T G, Andricevic M, Wass H. Remission of cold hemagglutinin disease induced by rituximab therapy. CMAJ 2001; 164: 1405
   PubMed Web of Science ®Google Scholar
• Zaja F, Russo D, Fuga G, Michelutti T, Sperotto A, Fanin R. Rituximab in a case of cold agglutinin disease. Br J Haematol 2001; 115: 232–233
   PubMed Web of Science ®Google Scholar
• Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 189–195
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen B T, Hjorth-Hansen H, Langholm R, Knutsen H. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103: 2925–2928
   PubMed Web of Science ®Google Scholar
• Issitt P D, Anstee D J. Applied Blood Group Serology. Montgomery Scientific Publications, Durham, NC 1998
   Google Scholar
• Engelhardt M, Jakob A, Ruter B, Trepel M, Hirsch F, Lubbert M. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 2002; 100: 1922–1923
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjonnfjord G E, Brudevold R, Gjertsen B T, Langholm R, Lokkevik E. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001; 115: 79–83
   PubMed Web of Science ®Google Scholar
• Byrd J C, Kitada S, Flinn I W, Aron J L, Pearson M, Lucas D. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038–1043
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G M, Bernasconi S. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, Gressin R, Molens J P, Jacob M C. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949–954
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581–1587
   PubMed Web of Science ®Google Scholar
• Teeling J L, French R R, Cragg M S, van den B J, Pluyter M, Huang H. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104: 1793–1800
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Berentsen S, Bo K, Shammas F V. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol 1999; 63: 259–266
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Berentsen S, Mollnes T E. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol 2001; 54: 239–242
   PubMed Web of Science ®Google Scholar